GSK Pays $31.5 Million Upfront, Plus Milestones To Access Angiochem’s Rare Disease Technologies GlaxoSmithKline takes aim at neurological symptoms of lysosomal storage diseases, increasing likely future competitive pressure on Sanofi's and Shire's rare disease products.
European Pharmacovigilance Update Still Causing Concern The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.
Ranbaxy Records $568 Million Loss For DoJ Penalty; Sees More Predictability In U.S. Business India’s Ranbaxy has reported mixed results as it tops $2 billion in sales but suffers $568 million in losses from a U.S. consent decree penalty.
EHR “Meaningful Use” Requirements Raise Expectations For Health Information Exchange In Stage 2 CMS highlights the greater role that health information exchange will play in stage 2 meaningful use for electronic health records and sets the stage for an even more robust use of health data to promote safety and efficiency as the agency moves toward stage 3.
CMS Interested In Part D Plan Collaboration With Medicare ACOs In a draft version of its annual instructions to Part D plans, CMS says it is seeking feedback from Part D sponsors and other stakeholders on “possible strategies for achieving better coordination” between stand-alone Medicare Part D plans and accountable care organizations to improve pharmacy care.
With FDA Clinical Hold Lifted, Idenix Hopes To Combine Its “Nuc” With A Protease Inhibitor For HCV Idenix’s IDX184 is the only unpartnered nucleoside polymerase inhibitor for hepatitis C in clinical development. With an FDA hold lifted, the company wants to make quick progress testing ‘184 in interferon-free regimens for HCV.
Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis
